Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Recurrence 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Brain Neoplasms 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Glioblastoma × marizomib × Clear all
NCT03345095 2025-07-01

MIRAGE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
749 enrolled 15 charts
CNS

Glioblastoma

NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡